methicillin-resistant Staph aureus (MRSA) infections in hospitalized patients
New guidelines will clarify treatment of methicillin-resistant Staph aureus (MRSA) infections in hospitalized patients.
Choose treatments based on the infection site, patient's age, antibiotic sensitivities, patient tolerance, cost, etc.
Keep in mind that the newer drugs (daptomycin, linezolid, telavancin) cost about $200 per day...ten times more than the older ones (clindamycin, TMP/SMX, vancomycin).
Get concise, unbiased advice for effective drug therapy, plus CE/CME
Prescriber's Letter includes:
- 12 issues every year, with brief articles about new meds and guidelines
- 48+ CE courses, including the popular CE-in-the-Letter
- Quick reference drug comparison charts
- Access to the entire archive
Already a subscriber? Log in
Volume pricing available. Get a quote